Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXIN PEDIATRIC vs CRYSTODIGIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Heart failure,Atrial fibrillation,Atrial flutter
Treatment of heart failure with reduced ejection fraction (FDA-approved),Control of ventricular response in atrial fibrillation and atrial flutter (FDA-approved)
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Hepatic via glucuronidation; substrate of P-glycoprotein; renal excretion of unchanged drug.
Primarily renal excretion; minimal hepatic metabolism. Not significantly metabolized by cytochrome P450 enzymes.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
20-30% bound to plasma proteins, primarily albumin.
~20–25% bound to plasma proteins, primarily albumin.
Vd is 5-10 L/kg in adults, indicating extensive tissue binding; higher in infants (up to 16 L/kg) with reduced protein binding.
Vd approximately 5–10 L/kg, indicating extensive tissue distribution; clinical significance: large Vd means low plasma concentration relative to total body load, necessitating loading doses.
Oral: 60-80% (Lanoxin Pediatric elixir 70-85%); variable due to first-pass metabolism and P-glycoprotein effects.
Oral: 60–80% (variable, depends on formulation and gastrointestinal factors); Intravenous: 100%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50%; GFR <10 m L/min: reduce dose by 50-75% or consider alternative.
Cr Cl 10-50 m L/min: reduce dose by 25-50%; Cr Cl <10 m L/min: reduce dose by 50-75% or use alternative.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50-75% with monitoring.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Oral loading: 10-20 mcg/kg in divided doses over 24 hours; maintenance: 5-10 mcg/kg once daily. IV loading: 10-15 mcg/kg; maintenance: 4-8 mcg/kg once daily. Monitor levels.
Loading dose: 10-20 mcg/kg intravenously over 2-4 hours; maintenance: 5-10 mcg/kg every 6 hours as needed.
Reduced dose: initial maintenance 0.0625-0.125 mg once daily due to age-related renal impairment and increased sensitivity. Monitor renal function and serum digoxin levels.
Start at lower end of dosing range (0.25 mg intravenously), adjust based on renal function and response, monitor for toxicity.
Digitalis toxicity can cause severe arrhythmias; monitoring of serum digoxin levels required.
None.
Risk of toxicity in renal impairment, electrolyte disturbances, and drug interactions; monitor digoxin levels and ECG.
Narrow therapeutic index; toxicity can be life-threatening.,Hypokalemia, hypomagnesemia, and hypercalcemia increase risk of digoxin toxicity.,Electrolyte monitoring and dose adjustment in renal impairment.,Patients with acute myocardial infarction, myocarditis, or severe pulmonary disease may be at increased risk of arrhythmias.
Hypersensitivity to digoxin, ventricular fibrillation, digitalis toxicity.
Ventricular fibrillation,Known hypersensitivity to digoxin or other digitalis glycosides,Hypercalcemia,Hypokalemia (uncorrected),Atrioventricular block (second- or third-degree) unless a pacemaker is present,Hypertrophic obstructive cardiomyopathy (relative contraindication)
Avoid concurrent ingestion of high-fiber foods, as they may reduce absorption. Separate dosing by at least 2 hours from meals rich in bran, oats, or other fiber. Maintain consistent dietary potassium intake; both low and high potassium can affect digoxin toxicity. Grapefruit juice may increase absorption; avoid excessive consumption.
Avoid high-fiber foods and large amounts of bran or pectin, as they may reduce absorption. Grapefruit juice may increase blood levels; limit consumption. Consistent dietary potassium intake is important; extremes (high or low) can affect drug action.
First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restriction due to transplacental transfer and maternal hemodynamic changes.
Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fetal bradycardia and hypoxia due to placental transfer. Third trimester: Risk of neonatal digitalis toxicity, including arrhythmias and heart block.
Digoxin is excreted into breast milk with an M/P ratio of approximately 0.6–0.9. Levels are low (typically <1 ng/m L) and considered compatible with breastfeeding; however, monitor infant for signs of toxicity including bradycardia and feeding difficulties.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.75-1.0). Considered compatible with breastfeeding; monitor infant for signs of toxicity (bradycardia, vomiting).
Due to increased volume of distribution and renal clearance in pregnancy, higher doses (up to 30–50% increase) may be required to maintain therapeutic serum levels. Monitor serum digoxin concentrations and titrate to therapeutic range (0.5–0.9 ng/m L in heart failure; 0.8–2.0 ng/m L for arrhythmias).
Increased volume of distribution and renal clearance in second and third trimesters may necessitate dose increases. Monitor serum digoxin levels and adjust to maintain therapeutic range (0.5-1.0 ng/m L).
Lanoxin Pediatric (digoxin) requires monitoring of renal function and serum electrolytes (especially potassium and magnesium) due to narrow therapeutic index. Check digoxin levels 6-8 hours after dose; therapeutic range 0.8-2.0 ng/m L. Avoid concurrent use with drugs that affect renal function or electrolyte balance.
Crystodigin (digitoxin) has a very long half-life (~5-7 days) requiring careful monitoring to avoid accumulation. Unlike digoxin, it is primarily hepatically metabolized, so renal impairment has less impact on dosing. Always check for drug interactions with CYP3A4 inducers/inhibitors. Therapeutic monitoring of serum levels is essential (target 15-25 ng/m L).
Take exactly as prescribed at the same time each day. Do not double the dose if you miss one.,Do not stop taking without consulting your doctor. Sudden withdrawal may worsen heart condition.,Watch for signs of toxicity: nausea, vomiting, diarrhea, vision changes (blurring, yellow-green halos), confusion, irregular heartbeat.,Keep all appointments for blood tests to monitor levels and kidney function.,Contact your doctor before taking any new medications, including over-the-counter drugs and supplements.,Limit alcohol and avoid potassium-sparing diuretics unless prescribed. Maintain consistent dietary intake of potassium-rich foods.
Take exactly as prescribed; do not miss doses or double up.,Report any symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), or irregular heartbeat.,Avoid over-the-counter medications without consulting your doctor, especially antacids and laxatives.,Keep regular appointments for blood tests to monitor drug levels and kidney function.,Do not stop suddenly; withdrawal can worsen heart condition.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXIN PEDIATRIC vs CRYSTODIGIN, answered by our medical review team.
LANOXIN PEDIATRIC is a Cardiac Glycoside that works by Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.. CRYSTODIGIN is a Cardiac Glycoside that works by Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXIN PEDIATRIC and CRYSTODIGIN depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXIN PEDIATRIC is: Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.. The standard adult dose of CRYSTODIGIN is: 0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXIN PEDIATRIC and CRYSTODIGIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXIN PEDIATRIC is classified as Category C. First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restric. CRYSTODIGIN is classified as Category C. Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.